DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20202187

A comparison of efficacy and safety with add on therapy of pioglitazone in adult patients of psoriasis with and without metabolic syndrome

Mahesh Chander Gupta, Kartik Nayak, Kamal Aggarwal

Abstract


Background: Psoriasis is a chronic disease involving skin with systemic manifestations whose etiology remains unknown. In recent times, an increased occurrence of metabolic syndrome has been seen in psoriatic patients and potential role of antihyperglycemic in such conditions is being evaluated.

Methods: This was a prospective, controlled, randomized, open label comparative clinical study conducted on 51 psoriatic patients. The patients were divided into two groups with and without MS and both these groups were further randomised to receive either standard therapy alone (topical 0.05% betamethasone dipropionate applied twice daily) or therapy with pioglitazone 15 mg orally once daily as add on to standard treatment. The study was conducted over a period of 12 weeks and the primary efficacy outcome was assessed by a change in psoriasis area severity index (PASI). The secondary outcomes were achievement PASI 50/75 and change in parameters of metabolic syndrome (MS). Change in quality of life assessed using dermatological life quality index (DLQI). 

Results: Both the treatments significantly reduced the PASI score in psoriatic patients with and without MS, maximum being at 12 weeks. In patients with and without MS, pioglitazone caused a greater reduction in PASI score and DLQI score though it was found comparable to ST alone. Significant improvement in parameters of metabolic syndrome was observed in pioglitazone treated group.

Conclusions: Pioglitazone given as add on therapy caused an additional improvement in clinical severity and QOL in both the group of psoriatic patients with and without metabolic syndrome. Role of pioglitazone needs to be further explored with higher recommended dose range (30 mg and 45 mg) to demonstrate the usefulness of this drug in psoriatic patients.


Keywords


Psoriasis, Psoriasis area and severity index, Dermatology life quality index

Full Text:

PDF

References


Queiro R, Tejon P, Alonso S, Coto P. Age at disease onset: a key factor for understanding psoriatic disease. Rheumatology. 2014;53(7):1178-85.

Boehncke WH. Etiology and pathogenesis of psoriasis. Rheum Dis Clin N Am. 2015;41(4):665-75.

Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: a comprehensive review. J Autoimmun. 2015;64:66-73.

Oliveira M, Rocha B, Duarte GV. Psoriasis: classical and emerging comorbidities. Anais Brasileiros de Dermatologia. 2015;90(1):9-20.

Parisi R, Rutter MK, Lunt M. Psoriasis and the risk of major cardiovascular events: cohort study using the Clinical Practice Research Datalink. J Invest Dermatol. 2015;135(9):2189-97.

Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137-74.

Bongartz T, Coras B, Vogt T, Scholmerich J, Ladner MU. Treatment of active psoriatic arthritis with the PPAR gamma ligand pioglitazone: an open-label pilot study. Rheumatology. 2005;44(1):126-9.

Liu Y, Yang F, Ma W, Sun Q. Metformin inhibits proliferation and proinflammatory cytokines of human keratinocytes in vitro via mTOR-signaling pathway. Pharm Biol. 2016;54(7):1173-8.

Badri AMR, Azar ST. Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis. Ther Adv Endocrinol Metab. 2014;5(2):34-8.

Komiya E, Hatano R, Otsuka H, Itoh T, Yamazaki H, Yamada T, et al. A possible role for CD26/DPPIV enzyme activity in the regulation of psoriatic pruritus. J Dermatol Sci. 2017;86(3):212-21.

Rajagopalan R, Iyer S, Khan M. Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials. Curr Med Res Opin. 2005;21(1):163-72.

Shafiq N, Malhotra S, Pandhi P, Gupta M, Kumar B, Sandhu K. Pilot trial: pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int J Dermatol. 2005;44(4):328-33.

Hafez VG, Bosseila M, Abdel MR, Shaker OG, Kamal M, Kareem HS. Clinical effects of ‘pioglitazone’, an insulin sensitizing drug, on psoriasis vulgaris and its co-morbidities, a double blinded randomized controlled trial 1. J Dermatolog Treat. 2015;26(3):208-14.

Enas E, Mohan V, Deepa M, Farooq S, Pazhoor S, Chennikkara H. The metabolic syndrome and dyslipidemia among Asian Indians: a population with high rates of diabetes and premature coronary artery disease. J Cardiometab Syndr. 2007;2(4):267-75.

Ashcroft DM, Wan AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999;141(2):185-91.

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-6.

World Health Organization (WHO) - Uppsala Monitoring Centre (UMC). Sweden: WHO-UMC Causality Assessment Scale; 2018. Available at: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHO causality_assess. Accessed on 21 May 2019.

Lajevardi V, Hallaji Z, Daklan S, Abedini R, Goodari A, Abdolreza M. The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial. Int J Dermatol. 2015;54(1):95-101.

Mittal R, Malhotra S, Pandhi P, Kaur I, Dogra S. Efficacy and safety of combination acitretin and pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: A randomized, double-blind, placebo-controlled clinical trial. Arch Dermatol. 2009;145(4):387-93.